181 results on '"Toniatti C"'
Search Results
2. Discovery of I-0436650, a potent and selective SHP2 allosteric inhibitor for the treatment of RAS driven solid tumors
3. Intratumor RNA interference of cell cycle genes slows down tumor progression
4. Gene therapy progress and prospects: transcription regulatory systems
5. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2s-M2 tetracycline transactivator and repressor system
6. 77 (PB067) - Discovery of I-0436650, a potent and selective SHP2 allosteric inhibitor for the treatment of RAS driven solid tumors
7. Interleukin (IL)-6 Gene Expression in the Central Nervous System Is Necessary for Fever Response to Lipopolysaccharide or IL-1[beta]: A Study on IL-6-deficient Mice
8. Coupling protein design and in vitro selection strategies: improving specificity and affinity of a designed ƒÒ-protein IL-6 antagonist
9. The affinity-selection of a minibody polypeptide inhibitor of human intereukin-6
10. IT-15 * DELTA-24-RGDOX: TARGETING CO-STIMULATORY IMMUNE CHECKPOINT PROTEINS WITH ONCOLYTIC ADENOVIRUSES
11. Regulation of the human C-reactive protein gene, a major marker of inflammation and cancer
12. constitutive and IL6 induced nuclear factors that interact with the human C reactive protein promoter
13. Role of IL-6 and its soluble IL-6 receptor in induction of chemokine and leukocyte recruitment
14. IL-6, in concert with soluble IL-6 receptor, selectively induces chemokine production in endothelial cells and participates in leukocyte recruitment in vivo
15. Laparoscopia ed endometriosi: le localizzazioni extragenitali
16. Human IL-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
17. 108 Parallel siRNA and Compound Screens to Identify Molecular Determinants of Sensitivity to WEE1 Inhibition in Breast Cancer
18. Multidimensional C-13, N-15 heteronuclear NMR-Spectroscopy of the H-interleukin-6
19. First-in-human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients with antitumor activity in BRCA-deficient tumors and sporadic ovarian cancers (soc).
20. First in human trial of the poly(ADP)-ribose polymerase inhibitor MK-4827 in patients with advanced cancer with antitumor activity in BRCA-deficient and sporadic ovarian cancers
21. GENERATION OF IL-6 ANTAGONISTS BY SUBSTITUTING RESIDUES IN HELIX-A
22. 362 First in human trial of a poly(ADP)-ribose polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (p) with antitumor activity in BRCA-deficient and sporadic ovarian cancers
23. First-in-human trial of a poly(ADP-ribose) polymerase (PARP) inhibitor MK-4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers.
24. Long-Term and Tight Control of Gene Expression in Mouse Skeletal Muscle by a New Hybrid Human Transcription Factor
25. The receptor super-antagonist Sant7
26. IL-6 is an in vitro and in vivo autocrine growth factor for middle T antigen-transformed endothelial cells.
27. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
28. Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.
29. Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans.
30. Interleukin (IL)-6 gene expression in the central nervous system is necessary for fever response to lipopolysaccharide or IL-1 beta: a study on IL-6-deficient mice.
31. The Molecular Design of Human IL‐6 Receptor Antagonistsa
32. Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.
33. Rational design of a receptor super-antagonist of human interleukin-6.
34. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6.
35. Oncostatin M binds directly to gp130 and behaves as interleukin-6 antagonist on a cell line expressing gp130 but lacking functional oncostatin M receptors
36. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp130 activation.
37. Synergistic trans-activation of the human C-reactive protein promoter by transcription factor HNF-1 binding at two distinct sites.
38. C-reactive protein gene expression is under control of transcription factor HNF1
39. Liver-specific and inducible expression of oncogenes in transgenic mice
40. Constitutive and IL-6-induced nuclear factors that interact with the human C-reactive protein promoter.
41. Tight control of gene expression by a helper-dependent adenovirus vector carrying the rtTA2s-M2 tetracycline transactivator and repressor system.
42. Dual control of C‐reactive protein gene expression by interleukin‐1 and interleukin‐6.
43. Monovalent phage display of human interleukin (hIL)-6: selection of superbinder variants from a complex molecular repertoire in the hIL-6 D-helix
44. Interleukin-6 (IL-6) antagonism by soluble IL-6 receptor alpha mutated in the predicted gp130-binding interface.
45. Down-regulation of interleukin 6 receptor alpha chain in interleukin 6 transduced melanoma cells causes selective resistance to interleukin 6 but not to oncostatin M
46. The receptor super-antagonist Sant7: A potent and safe inhibitor of IL-6 on human myeloma cells (review)
47. Human interleukin-6 receptor super-antagonists with high potency and wide spectrum on multiple myeloma cells
48. Inhibition of retinal and choroidal neovascularization by a novel KDR kinase inhibitor
49. Two distinct and independent sites on IL-6 trigger gp130 dimer formation and signalling
50. Down-Regulation of Interleukin 6 Receptor a Chain in Interleukin 6 Transduced Melanoma Cells Causes Selective Resistance to Interleukin 6 but not to Oncostatin M
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.